Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
NEC OncoImmunity AS
Empowering cancer immunotherapy with artificial intelligence
TL;DR
What they do: AI-driven biotech focused on neoantigen prediction, personalized cancer vaccines, and B-cell epitope prediction for infectious diseases
Headquarters: Oslo, Norway (Forskningsparken / Oslo Science Park)
Corporate ownership: Subsidiary of NEC Bio B.V. (NEC Corporation group)
Notable backers: Coalition for Epidemic Preparedness Innovations (CEPI) and EASME (grant funder) reported
Team size (reported): ~30 employees
Company Overview
Problem Domain
Cancer immunotherapy and infectious-disease vaccine antigen design
Industry
Biotechnology / Bioinformatics / Immuno-oncology
Funding Track Record
Seed round listed on Crunchbase with CEPI as lead
Grant funding / investor activity noted in 2017–2018 entries
Acquired by NEC Corporation and organized under NEC Bio B.V.
Investor Signal
“CEPI and EASME involvement; acquisition by NEC Corporation”
Founders
What we do
Join the Team
Startup jobs. A lot of them.
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
60,000+
Open Roles
200+
New This Week